Vi-specific serological correlates of protection for typhoid fever

Author:

Jin Celina12ORCID,Hill Jennifer12ORCID,Gunn Bronwyn M.3ORCID,Yu Wen-Han3ORCID,Dahora Lindsay C.4ORCID,Jones Elizabeth12ORCID,Johnson Mari12ORCID,Gibani Malick M.12ORCID,Spreng Rachel L.4ORCID,Alam S. Munir4ORCID,Nebykova Anna12ORCID,Juel Helene B.12ORCID,Dennison S. Moses4ORCID,Seaton Kelly E.4ORCID,Fallon Jonathan K.3ORCID,Tomaras Georgia D.4ORCID,Alter Galit3ORCID,Pollard Andrew J.12ORCID

Affiliation:

1. Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK

2. National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK

3. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA

4. Departments of Immunology, Surgery, and Molecular Genetics and Microbiology, Duke Human Vaccine Institute, Duke University, Durham, NC

Abstract

Typhoid Vi vaccines have been shown to be efficacious in children living in endemic regions; however, a widely accepted correlate of protection remains to be established. We applied a systems serology approach to identify Vi-specific serological correlates of protection using samples obtained from participants enrolled in an experimental controlled human infection study. Participants were vaccinated with Vi-tetanus toxoid conjugate (Vi-TT) or unconjugated Vi-polysaccharide (Vi-PS) vaccines and were subsequently challenged with Salmonella Typhi bacteria. Multivariate analyses identified distinct protective signatures for Vi-TT and Vi-PS vaccines in addition to shared features that predicted protection across both groups. Vi IgA quantity and avidity correlated with protection from S. Typhi infection, whereas higher fold increases in Vi IgG responses were associated with reduced disease severity. Targeted antibody-mediated functional responses, particularly neutrophil phagocytosis, were also identified as important components of the protective signature. These humoral markers could be used to evaluate and develop efficacious Vi-conjugate vaccines and assist with accelerating vaccine availability to typhoid-endemic regions.

Funder

Bill and Melinda Gates Foundation

European Commission

Seventh Framework Programme

National Institute for Health Research

Duke University

National Institutes of Health

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3